QUOTED. 10 December. Sara Barrington.
Kantaro Biosciences, a joint venture between Mount Sinai Health System and Renalytix AI, expects its SARS-COV-2 IgG antibody test kit will allow researchers and public health officials to track the effectiveness of the COVID-19 vaccination programs that will likely begin soon. See what Kantaro’s chief commercial officer Sara Barrington said about it here.
“Accessibility is going to be very important, especially as we're going into sort of a messy part of the transition in the pandemic.” – Sara Barrington, chief commercial officer, Kantaro
Click here for a free trial of Medtech Insight